Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company dedicated to developing cutting-edge therapies for treating cancer and other immune-mediated diseases. The company's core focus lies in pioneering allogeneic invariant natural killer T (iNKT) cell therapies, which are designed to be off-the-shelf solutions, making them readily available for patients in need.
MiNK's flagship program, agenT-797, is currently in a Phase 2 trial aimed at treating second-line gastroesophageal cancer. This trial, led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center, builds on promising results from earlier studies where agenT-797 demonstrated the ability to overcome resistance to immune checkpoint inhibitors. The trial is exploring the combination of agenT-797 with other advanced treatments, such as botensilimab and balstilimab, to improve outcomes for patients with challenging gastrointestinal cancers.
Another significant candidate in MiNK's pipeline is MiNK-215, an IL-15 armored FAP-targeting CAR iNKT cell therapy. This candidate has shown remarkable efficacy in preclinical models for colorectal cancer liver metastases, overcoming the immune barriers typically posed by liver metastases.
The company recently reported a strong year-end financial position with ongoing collaborations, including a research agreement with ImmunoScape. MiNK Therapeutics continues to advance its clinical programs while maintaining a focus on scalable and reproducible manufacturing processes for its iNKT cell therapies.
Founded and headquartered in New York, NY, MiNK Therapeutics remains committed to delivering innovative and effective treatments for life-threatening diseases. For more information, visit their website or follow them on social media at @MiNK_iNKT.
MiNK Therapeutics (NASDAQ: INKT) has announced its return to full compliance with Nasdaq Capital Market listing requirements. The company has successfully met both the minimum bid price and market value requirements for continued listing, resolving previous compliance issues.
MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company maintains a pipeline of native and next-generation engineered iNKT programs, with a platform designed for scalable and reproducible manufacturing for off-the-shelf delivery.
MiNK Therapeutics (NASDAQ: INKT) has been selected to present interim data from its ongoing Phase 2 study at the AACR IO Annual Meeting in Los Angeles. The presentation will focus on their investigation of AgenT-797 in combination with botensilimab and balstilimab (BOT/BAL) for treating refractory gastric cancer patients.
The study specifically targets patients with PD-1 refractory gastroesophageal cancer (GEC) who have received second-line or later treatment. The presentation, scheduled for February 25th, will include biomarker analysis from the trial combining iNKT cell therapy with CTLA-4 and PD-1 inhibitors.
MiNK Therapeutics (NASDAQ: INKT) announced a presentation at the ASCO GI Symposium, highlighting their novel combination therapy approach for advanced gastroesophageal cancers. The company is conducting a Phase 2 trial at Memorial Sloan Kettering Cancer Center, combining agenT-797 (iNKT cells) with botensilimab/balstilimab (BOT/BAL) plus ramucirumab and paclitaxel for previously treated patients.
Previous Phase 1 trial data showed durable responses and tolerability in PD-1 refractory cancers, with gastric cancer patients demonstrating significant clinical and immunologic responses. The company plans to provide a clinical update from the ongoing Phase 2 study in the second half of 2025.
CEO Dr. Jennifer Buell emphasized that iNKT cells play a important role in immune reconstitution, while BOT/BAL enhances T-cell priming and eliminates immunosuppressive regulatory cells, creating a comprehensive approach to make disease biologically unsustainable.
MiNK Therapeutics (NASDAQ: INKT) has announced an upcoming presentation at the ASCO GI Symposium in San Francisco from January 23-25, 2025. The presentation will focus on their ongoing Phase 2 study of agenT-797, an invariant natural killer T (iNKT) cell therapy, combined with Agenus' botensilimab/balstilimab for treating refractory gastric cancer.
The abstract (TPS515), titled 'A phase II study of agenT-797, botensilimab, and balstilimab in patients with advanced, refractory gastroesophageal adenocarcinoma,' will be presented by Dr. Samuel Cytryn during the Trials in Progress Poster Session on January 23, 2025. Complete abstracts will be released on January 21st, 2025, at 5:00 PM ET, with presentation materials later available on MiNK's website.
MiNK Therapeutics reported Q3 2024 financial results and business updates. The company ended Q3 with $6.3 million cash balance, with reduced cash burn of $3 million for Q3 and $7.8 million for nine months of 2024. Net loss was $1.8 million ($0.05 per share) for Q3 and $8.3 million ($0.22 per share) for nine months.
Key developments include Dr. Robert Kadlec joining the Board, a research collaboration with Autonomous Therapeutics for metastatic tumors, and two presentations at SITC 2024. The company's Phase 2 trial for gastric cancer is ongoing with data expected in early 2025, and a Phase 1 GvHD trial is planned for 2025.
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on invariant natural killer T (iNKT) cell therapies, announced it will release its third quarter 2024 financial results before market opens on November 14, 2024. The company will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a corporate update. The event will be accessible via phone and webcast through the company's investor relations website.
MiNK Therapeutics presented new data at SITC 2024 showcasing their iNKT cell therapy programs. Their lead therapy agenT-797, alone or combined with anti-PD-1, demonstrated durable disease control in heavily pretreated patients. When combined with bispecific engagers targeting MUC16, HER2, Claudin 18.2, and DLL3, it showed enhanced T-cell activation and tumor cell killing.
The company also presented data on their PRAME-TCR iNKT therapy, designed to treat PRAME-positive solid tumors without requiring lymphodepletion or HLA-matching. A Phase 2 trial of agenT-797 is currently enrolling patients with advanced gastroesophageal cancer, with results expected in 2025.
MiNK Therapeutics (NASDAQ: INKT) has appointed Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec, former U.S. Assistant Secretary for Preparedness and Response at HHS, brings extensive expertise in biodefense and pandemic preparedness. He previously co-conceived Operation Warp Speed and directed pandemic response for HHS during COVID-19. His appointment aims to accelerate MiNK's development of allogeneic off-the-shelf invariant natural killer T (iNKT) cell therapies for infectious diseases, including pathogen-agnostic acute respiratory distress syndrome (ARDS) and emerging threats.
MiNK Therapeutics (NASDAQ: INKT) announced two poster presentations at the Society for Immunotherapy of Cancer's 29th Annual Meeting in Houston, Texas, from November 6-10, 2024. The presentations will showcase new preclinical data from MiNK's iNKT cell programs, agenT-797 and PRAME-TCR.
The first presentation, titled 'AgenT-797 cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and / or bi-specific engagers to improve anticancer response,' is scheduled for Friday, November 8th (Abstract Number: 753).
The second presentation, 'PRAME-TCR iNKT cell therapy: Opportunity for best-in-class off-the-shelf solid tumor therapy targeting PRAME,' will take place on Saturday, November 9th (Abstract Number: 374).
MiNK Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases.
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focusing on allogeneic iNKT cell therapies, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024. Dr. Jennifer Buell, CEO of MiNK, will engage in a fireside chat on Monday, September 9th at 7:00 a.m. ET.
Investors can register for the event online, and a replay will be available on MiNK's website afterward. This conference provides an opportunity for MiNK to showcase its progress in developing innovative therapies for cancer and other immune-mediated diseases to a global investment audience.
FAQ
What is the current stock price of Mink Therapeutics (INKT)?
What is the market cap of Mink Therapeutics (INKT)?
What does MiNK Therapeutics specialize in?
What is agenT-797?
What are the recent achievements of MiNK Therapeutics?
Where is MiNK Therapeutics headquartered?
What partnerships has MiNK Therapeutics established?
What is MiNK-215?
How does MiNK Therapeutics deliver their therapies?
How can investors get more information about MiNK Therapeutics?
What is the primary focus of MiNK Therapeutics' current research?
How does agenT-797 work?
